{"id":3758,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1991-04-02","marketCap":111328.5234375,"name":"Regeneron Pharmaceuticals Inc","phone":"17813705000","outstanding":110.19000244140625,"symbol":"REGN","website":"https://www.regeneron.com/","industry":"Biotechnology"},"price":1005.67,"year":2024,"month":6,"day":12,"weekday":"Wednesday","title":"Corporate Governance Practices of Regeneron Pharmaceuticals Inc","date":"2024-06-12","url":"/posts/2024/06/12/REGN","content":[{"section":"Board Composition","text":"Regeneron Pharmaceuticals Inc has a well-composed board with a diverse range of expertise and experience. The board consists of 12 members, including both executive and non-executive directors. The board members have backgrounds in areas such as pharmaceuticals, biotechnology, finance, and healthcare. This diverse composition ensures that the board can effectively oversee the company's operations and make informed decisions."},{"section":"Executive Compensation","text":"Regeneron Pharmaceuticals Inc follows a transparent approach to executive compensation. The company discloses detailed information regarding executive compensation in its annual proxy statement. The compensation structure is designed to align the interests of executives with shareholders, with a focus on long-term performance. The company uses a mix of base salary, annual incentives, and long-term equity-based incentives to compensate its executives. Overall, the executive compensation practices are in line with industry standards and aim to attract and retain top talent while ensuring alignment with shareholder interests."},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""}],"tags":["LongSignals","Long","Biotechnology"],"news":[{"category":"company","date":1718129160,"headline":"Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion","id":128207418,"image":"https://media.zenfs.com/en/zacks.com/f84faa3d65021260b4cd14c75493ef6c","symbol":"REGN","publisher":"Yahoo","summary":"The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.","url":"https://finance.yahoo.com/news/regeneron-regn-sny-win-fda-180600299.html"},{"category":"company","date":1718115420,"headline":"Regeneron and Sanofi get FDA approval for juvenile arthritis treatment","id":128204611,"image":"","symbol":"REGN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=pwu99jvci1"},{"category":"company","date":1718103600,"headline":"Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)","id":128207419,"image":"https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142","symbol":"REGN","publisher":"Yahoo","summary":"Approval in patients with pJIA weighing 63kg or greater adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica TARRYTOWN, N.Y. and CAMBRIDGE, MA, June 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara® (sarilumab) for the treatment of patients weighing 63 kg or greater with activ","url":"https://finance.yahoo.com/news/kevzara-sarilumab-approved-fda-treatment-110000426.html"},{"category":"company","date":1718100425,"headline":"Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)","id":128198297,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"REGN","publisher":"SeekingAlpha","summary":"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 8:00 AM ETCompany ParticipantsRyan...","url":"https://seekingalpha.com/article/4698613-regeneron-pharmaceuticals-inc-regn-goldman-sachs-45th-annual-global-healthcare-conference"},{"category":"company","date":1718088600,"headline":"Regeneron, Sanofi win FDA label expansion for arthritis therapy Kevzara","id":128204612,"image":"","symbol":"REGN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3535811056"},{"category":"company","date":1718085780,"headline":"Regeneron, Sanofi announce FDA approved Kevzara for treatment of pJIA","id":128204614,"image":"","symbol":"REGN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3535768115"},{"category":"company","date":1718071800,"headline":"Regeneron wins injunction blocking Mylan from launching generic version of its eye drug Eylea (update)","id":128205856,"image":"","symbol":"REGN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3536332315"},{"category":"company","date":1718071140,"headline":"Regeneron wins injunction blocking Mylan from launching generic version of its eye drug Eylea","id":128205857,"image":"","symbol":"REGN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3536317502"},{"category":"company","date":1718070720,"headline":"Mylan injunction an 'incremental positive' for Regeneron, says Morgan Stanley","id":128205858,"image":"","symbol":"REGN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3536310025"},{"category":"company","date":1718070480,"headline":"Regeneron wins permanent injunction blocking generic version of its eye drug Eylea","id":128205859,"image":"","symbol":"REGN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3536304825"},{"category":"company","date":1718067147,"headline":"2 Biotech Stocks For Your June 2024 Watchlist","id":128190427,"image":"https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2024/06/top-biotech-stocks-to-buy.jpg","symbol":"REGN","publisher":"StockMarket","summary":"Biotech stocks to check out in the stock market now.","url":"https://stockmarket.com/featured/2-biotech-stocks-for-your-june-2024-watchlist-2024-06-10"},{"category":"company","date":1717844416,"headline":"Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance A Reflection Of Its Financial Health?","id":128162105,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"REGN","publisher":"Yahoo","summary":"Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Since the market usually pay for a...","url":"https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-nasdaq-regn-110016998.html"},{"category":"company","date":1717769400,"headline":"Stock Split Watch: 3 Growth Stocks That Could Be Next","id":128139788,"image":"https://g.foolcdn.com/editorial/images/779610/person-working-on-a-laptop.jpg","symbol":"REGN","publisher":"Yahoo","summary":"Success has some downsides, including a much higher stock price.","url":"https://www.fool.com/investing/2024/06/07/stock-split-watch-3-growth-stocks-that-could-be-ne/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;referring_guid=e15bd765-679d-40cc-aad3-c330ac7eae6b\u0026amp;.tsrc=rss"},{"category":"company","date":1717724040,"headline":"Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside","id":128144588,"image":"","symbol":"REGN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3531296680"},{"category":"company","date":1717677532,"headline":"FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward","id":128118047,"image":"https://media.gettyimages.com/id/2150068563/photo/laboratory-mask-and-woman-with-plants-magnifying-glass-for-research-and-safety-in-medical.jpg?b=1\u0026s=170667a\u0026w=0\u0026k=20\u0026c=rLEGJgWmXaH2UjXDsaTHDklmaa0znozb8ypISUIUgUQ=","symbol":"REGN","publisher":"SeekingAlpha","summary":"FibroGen, Inc. has made strides in cancer treatment, with good results in pancreatic cancer \u0026 prostate cancer, catalysts expected in 2024. Read more here.","url":"https://seekingalpha.com/article/4697818-fibrogen-two-new-in-licensed-oncology-drugs-to-carry-it-forward"},{"category":"company","date":1717668120,"headline":"Biotech Alert: Searches spiking for these stocks today","id":128116701,"image":"","symbol":"REGN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3529299345"},{"category":"company","date":1717667520,"headline":"Goldman cuts 2seventy bio to neutral, cites competition concerns","id":128118151,"image":"","symbol":"REGN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3529284986"},{"category":"company","date":1717664830,"headline":"ASCO 2024 Round-Up: Some Of The Most Impactful Cancer News Out Of The Big Meeting","id":128114843,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/162762923/image_162762923.jpg?io=getty-c-w1536","symbol":"REGN","publisher":"SeekingAlpha","summary":"Biotech companies presented at this year's Annual Meeting of the American Society of Clinical Oncology. Find out the latest advancements in cancer treatment.","url":"https://seekingalpha.com/article/4697758-asco-2024-round-up-most-impactful-cancer-news-out-of-big-meeting"},{"category":"company","date":1717591389,"headline":"Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript)","id":128092803,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"REGN","publisher":"SeekingAlpha","summary":"Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Jefferies 2024 Global Healthcare Conference June 5, 2024 8:30 AM ETCompany ParticipantsMark Hudson -...","url":"https://seekingalpha.com/article/4697590-regeneron-pharmaceuticals-inc-regn-management-presents-jefferies-2024-global-healthcare"},{"category":"company","date":1717558920,"headline":"Regeneron Pharmaceuticals Now #88 Largest Company, Surpassing Chubb","id":128106233,"image":"","symbol":"REGN","publisher":"The Online Investor","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3528036694"},{"category":"company","date":1717526640,"headline":"Health Care Stocks Show Relative Strength as S\u0026P 500 Stalls","id":128075710,"image":"https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958","symbol":"REGN","publisher":"Yahoo","summary":"Several stocks are breaking out and trading near all-time highs.","url":"https://finance.yahoo.com/news/health-care-stocks-show-relative-184400079.html"},{"category":"company","date":1717491960,"headline":"Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals","id":128071662,"image":"","symbol":"REGN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3525876998"},{"category":"company","date":1717484880,"headline":"RBC Capital Sticks to Its Buy Rating for Regeneron (REGN)","id":128071663,"image":"","symbol":"REGN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3525746884"},{"category":"company","date":1717484580,"headline":"Regeneron price target raised by $15 at RBC Capital, here's why","id":128070898,"image":"","symbol":"REGN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3525742399"},{"category":"company","date":1717446140,"headline":"Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?","id":128061347,"image":"https://s.yimg.com/ny/api/res/1.2/HmNvCFXA56FVniZO2dMVhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/ce12dc684b7407c6d1e9f9e30c9fb7d9","symbol":"REGN","publisher":"Yahoo","summary":"We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is the best bet in the gene therapy sector. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]","url":"https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-nasdaq-regn-202220324.html"},{"category":"company","date":1717414032,"headline":"Sanofi - Dupixent recommended for EU approval by the CHMP to treat patients with COPD","id":128046086,"image":"","symbol":"REGN","publisher":"Finnhub","summary":"Paris - The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of Dupixent in the European Union as an add-on...","url":"https://finnhub.io/"},{"category":"company","date":1717396020,"headline":"Buy Rating Affirmed for REGN on Dupixent’s Strong Prospects Despite PDUFA Delay","id":128050457,"image":"","symbol":"REGN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3523950585"},{"category":"company","date":1717389600,"headline":"FibroGen stock rallies 30% after hours on FG-3165, FG-3175 updates","id":128071665,"image":"","symbol":"REGN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3524755740"},{"category":"company","date":1717384680,"headline":"FibroGen, Regeneron in deal for oncology assets in evaluation combo study","id":128071666,"image":"","symbol":"REGN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3524633827"},{"category":"company","date":1717376580,"headline":"Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today","id":128050459,"image":"","symbol":"REGN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3524439633"},{"category":"company","date":1717290120,"headline":"Emerging and Chinese pharmas playing greater role in oncology drug development","id":128038625,"image":"","symbol":"REGN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3523266285"},{"category":"company","date":1717169030,"headline":"FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease","id":128006992,"image":"https://media.zenfs.com/en/Benzinga/4639cde4168aaca1cd821ebede2d1e9a","symbol":"REGN","publisher":"Yahoo","summary":"On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually caused by smoking. The revised target action date is September 27, 2024. The FDA accepted the application in February, with a target action date of June 27, 2024. The FDA did not raise any concerns regardi","url":"https://finance.yahoo.com/news/fda-extends-review-deadline-regeneron-152350762.html"},{"category":"company","date":1717162500,"headline":"FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD","id":128006993,"image":"https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","symbol":"REGN","publisher":"Yahoo","summary":"Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.","url":"https://finance.yahoo.com/news/fda-delays-decision-sanofi-sny-133500498.html"},{"category":"company","date":1717144860,"headline":"Analysts Conflicted on These Healthcare Names: Merit Medical Systems (MMSI) and Regeneron (REGN)","id":128008187,"image":"","symbol":"REGN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3520537897"},{"category":"company","date":1717134600,"headline":"Regeneron/ Sanofi say FDA has delayed Dupixent COPD label","id":128008191,"image":"","symbol":"REGN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3520361950"},{"category":"company","date":1717131900,"headline":"Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD","id":127993947,"image":"https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142","symbol":"REGN","publisher":"Yahoo","summary":"Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announ","url":"https://finance.yahoo.com/news/dupixent-dupilumab-recommended-eu-approval-050500479.html"},{"category":"company","date":1717131600,"headline":"Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation","id":127993948,"image":"https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142","symbol":"REGN","publisher":"Yahoo","summary":"TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The revised target action date is Septe","url":"https://finance.yahoo.com/news/fda-priority-review-dupixent-dupilumab-050000009.html"},{"category":"company","date":1717129380,"headline":"Regeneron, Sanofi report FDA extension of target action date for Dupixent review","id":128008193,"image":"","symbol":"REGN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3520287895"},{"category":"company","date":1717129080,"headline":"Regeneron, Sanofi announce CHMP opinion recommending approval of Dupixent","id":128008194,"image":"","symbol":"REGN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3520284263"},{"category":"company","date":1717120740,"headline":"Dupixent by Regeneron, Sanofi recommended for new EU approval by panel","id":128007330,"image":"","symbol":"REGN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=ikp3vp8y2x"},{"category":"company","date":1717120080,"headline":"Buy Rating Affirmed for Regeneron Despite FDA Delay on Dupixent for COPD","id":128008198,"image":"","symbol":"REGN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3520933169"},{"category":"company","date":1717090868,"headline":"Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN","id":127983277,"image":"","symbol":"REGN","publisher":"Finnhub","summary":"NEW YORK, May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc.  .  Such investors are advised to contact Danielle Peyton at...","url":"https://finnhub.io/"},{"category":"company","date":1717058743,"headline":"Biohaven doses first subject in Phase I/II tumour treatment study","id":127974411,"image":"https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/05/Biohaven-shutterstock_2390581107.jpg","symbol":"REGN","publisher":"Yahoo","summary":"The trial is structured into two segments: a Phase I dose escalation and a multicohort Phase II dose expansion.","url":"https://www.clinicaltrialsarena.com/news/biohaven-tumour-treatment-study/"},{"category":"company","date":1717040580,"headline":"Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains","id":128008205,"image":"","symbol":"REGN","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3519286002"},{"category":"company","date":1716993914,"headline":"3 Of My Favorite Names On Wells Fargo's Biotech Buyout List","id":127958203,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183862006/image_183862006.jpg?io=getty-c-w1536","symbol":"REGN","publisher":"SeekingAlpha","summary":"Discover potential buyout targets in midcap biotech/biopharma stocks, selected by Wells Fargo, and see three personal favorites to consider. Click for the picks.","url":"https://seekingalpha.com/article/4696275-3-of-my-favorite-names-on-wells-fargos-biotech-buyout-list"},{"category":"company","date":1716981300,"headline":"Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors","id":127953551,"image":"https://media.zenfs.com/en/prnewswire.com/2252bec92abad49fb98226cf1ae2affb","symbol":"REGN","publisher":"Yahoo","summary":"Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven's g","url":"https://finance.yahoo.com/news/biohaven-doses-first-patient-novel-111500048.html"},{"category":"company","date":1716979920,"headline":"AstraZeneca touts PCSK9 inhibitor in lowering LDL cholesterol when added to statin","id":127956498,"image":"","symbol":"REGN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3517085823"},{"category":"company","date":1716971640,"headline":"Biohaven stock falls 30% premarket amid drug updates","id":127955865,"image":"","symbol":"REGN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3516916755"}]}